By importing quality generic products from Cipla or Ranbaxy Laboratories on a large scale, governments could steer apparent crisis courses back onto the path of recovery.
Through a sustained and intensive awareness and education effort, the use of intravenous drugs could be substantially curbed. With the number of users decreased, the number of new HIV/AIDS cases would also be limited, allowing hospitals and governmental and non-governmental (NGO) organizations to focus their labors on those already infected.